Physician profile
Laura Corsello
NPI 1457357097
$1,259.16
in general payments reported to CMS, 2019-2025
10 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $565 · 2024: $407 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,259.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $590.83 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $414.57 | 2023-2025 | |
| Astrazeneca Pharmaceuticals Lp | $64.87 | 2024-2025 | Airsupra |
| Lilly USA, LLC | $49.82 | 2025 | Zepbound, Mounjaro |
| Pfizer INC. | $36.45 | 2023-2024 | |
| Glaxosmithkline, LLC. | $26.24 | 2025 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $21.96 | 2023 | Verquvo |
| Esperion Therapeutics, INC. | $21.65 | 2024 | Nexletol |
| Abbvie INC. | $19.43 | 2023 | Linzess, Viberzi |
| Phadia US INC. | $13.34 | 2023 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Corsello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.